Connect with us

BioPharma

Darkpulse Inc (OTCMKTS: DPLS) On the Move Northbound Again as BOTDA & Optilan Move Forward

Published

2 years ago

on

Darkpulse Inc (OTCMKTS: DPLS) is making a powerful move up the charts in recent days off its base at a dime on heavy volume easily topping $5 million in dollar volume on Monday alone.  The stock is getting noticed by some pretty heavy hitter penny stock players and is currently among the most talked about and searched for stocks in small caps. Currently under heavy accumulation DPLS is looking to breakout into a whole new dimension. With recent highs set at $0.202 the stock will really take off once it breaks through this intraday high. Darkpulse is a leader in distributed fibre sensor solutions. The Companies system outperforms all other distributed fiber sensors in the market today. DarkPulse’s growing list of world-class capabilities and the Company’s positioning as the leader in infrastructure sensing and monitoring in all domains, air, land, and sea which represents an enormous market worth billions puts the Company in line for serious government contracts according to many investors who are buying in here.  

Darkpuse has been making big moves with the acquisiton of Optilan which recently secured leases for two new facilities located in Warwickshire in the U.K. The new facilities reinforce the Company’s innovative culture and commitment to providing industry-leading technology. The Company and Optilan have leased a new manufacturing and storage facility and a separate U.K.-based office headquarters (HQ). These new facilities represent a number of key investments the Company and Optilan are currently making to support future growth aspirations including the recently rolled out Enterprise Resource Planning system (ERP). Warwickshire is recognised as a regional hub for world class research, manufacturing, and engineering services, which reflects the positioning of the Company and Optilan. Darkpulse also just launched its Precise Point Emissions Services utilizing “around the block or around the world” capabilities. The Company’s methane detection platform comprises world class laser systems including the AILF U – 10 laser methane leak detector flown on DJI UAV platforms by Remote Intelligence and TerraData Unmanned. These platforms can locate the precise point source of fugitive methane emissions and display data anywhere on any device with an AI powered globally available User Interface. 

Darkpulse Inc (OTCMKTS: DPLS) uses advanced laser-based monitoring systems to provide rapid and accurate monitoring of temperatures, strains and stresses. The Company’s technology excels when applied to live, dynamic critical infrastructure and structural monitoring, including pipeline monitoring, perimeter and structural surveillance, aircraft structural components and mining safety. The Company’s fiber-based monitoring systems can assist markets that are not currently served, and its unique technology covers extended areas and any event that is translated into the detection of a change in strain or temperature. In addition to the Company’s ongoing efforts with respect to the marketing and sales of its technology products and services to its customers, the Company also continues to explore potential strategic alliances through joint venture and licensing opportunities to further expand its global market position. 

Darkpulse is a leader in distributed fiber sensor solutions. DPLS system outperforms all other distributed fiber sensors in the market today. DarkPulse’s growing list of world-class capabilities and the Company’s positioning as the leader in infrastructure sensing and monitoring in all domains, air, land, and sea which represents an enormous market worth billions puts Darkpulse in line for serious government contracts according to many investors who are buying in here. The Company continues to grow fast through acquisition. 

In this video engineers demonstrate the function of the dark-pulse based BOTDA system measuring strain on a PVC pipe. A 4″ PVC pipe specimen with 12′ length has a sensing fibre helically wrapped around it which measures the hoop strain as the pressure in the pipe is raised. Data is first collected at an internal pressure of 10 psig. The engineers then clamp one end of the pipe creating a disturbance in the strain field. This disturbance is readily seen in the second measurement demonstrating dark-pulse BOTDA system’s ability to detect sub-metre strain events. Data collection takes a matter of seconds. Processing the data takes somewhat longer, however in this instance is a result of the limited computing power of the Raspberry Pi processor utilized during the demonstration. DarkPulse offers multiple configurations with increased processor capacity for faster data display including a cloud based GUI as part of 24/7 structural health monitoring solutions.

On August 10 DPLS closed the acquisition of Optilan, a private company incorporated in England and Wales. Under the terms of the agreement, DarkPulse has acquired 100% of Optilan for cash considerations. The Company will invest additional resources for Optilan’s ongoing operations including working capital, expansion of the business and growth strategies as the two company’s work to solidify joint operations. “This new partnership comes at a crucial time and DarkPulse’s technology will fit many of our client’s needs. We have worked tirelessly to deliver our ambitious strategic vision and improve our structure, efficiency, and sustainability. I am exceptionally proud and excited that DarkPulse has decided to support our future development and for us to be a part of their team. Momentum has been building at pace in Optilan during the last twelve months and this acquisition will only increase the speed of our expansion ambitions.” said Bill Bayliss, CEO for Optilan. 

Optilan has secured leases for two new facilities located in Warwickshire in the U.K. The new facilities reinforce the Company’s innovative culture and commitment to providing industry-leading technology. The Company and Optilan have leased a new manufacturing and storage facility and a separate U.K.-based office headquarters (HQ). These new facilities represent a number of key investments the Company and Optilan are currently making to support future growth aspirations including the recently rolled out Enterprise Resource Planning system (ERP). Warwickshire is recognised as a regional hub for world class research, manufacturing, and engineering services, which reflects the positioning of the Company and Optilan. The new Manufacturing and Storage facility has been fitted out with all necessary modern equipment to support the delivery of security and telecommunication integrated systems. This investment reinforces the Company’s innovative culture and commitment to providing industry-leading technology. 

To Find out the inside Scoop on DPLS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DPLS

DPLS started running in early January which we reported on at the time stating: Darkpulse Inc (OTCMKTS: DPLS) is making a strong move up in recent weeks off its triple zero lows to recent highs over $0.02. DPLS has attracted legions of new shareholders and is quickly emerging as a volume leader in small caps topping $13 million in dollar volume on Friday alone. DPLS is making a number of big moves including building up its management team recently appointing Mr. Faisal Farooqui as its Director for Asia-Pacific (“APAC”) and Middle East and North Africa (“MENA”) global regions. Last week in a letter to shareholders, CEO Dennis O’Leary made a number of important points: “Since early 2020 we have made significant progress with the commercialization of our patents as well as building a global presence that will be part of the company’s accelerated entry into global infrastructure markets. With these exciting developments the momentum is continuing into 2021. After appointing company board members and creating a solid Leadership Team, our trajectory and rate of accomplishments have significantly accelerated.” Recently Darkpulse signed a MOU with TSK Korea to create a manufacturing and logistics presence in South Korea. 

Recently Darkpulse closed the acquisition of TerraData Unmanned, PLLC a drone based company offering multiple platform capabilities, including underwater inspection services. TerraData offers fully integrated, drone-based, geo-rectified, 3D modeled mapping for industrial applications including transportation departments, water management agencies, and engineering firms. TerraData inspects culverts, bridges, piers, dam and lock systems, water treatment facilities and more. 

TerraData joins DarkPulse’s growing list of world-class capabilities and the Company’s positioning as the leader in infrastructure sensing and monitoring in all domains, air, land, and sea. TerraData provides unique services critical in countering the increasing public safety concern related to bridges, culverts, dams, and similar infrastructure. TerraData’s ROV Inspection Services are needed more than ever as the United States struggles to assess conditions and deterioration of aging infrastructure. Specializing in underwater inspection through their unmanned vehicles (UUV), TerraData mitigates the safety concerns surrounding human divers. 

On November 3 Darkpulse launched its Precise Point Emissions Services utilizing “around the block or around the world” capabilities. The Company’s methane detection platform comprises world class laser systems including the AILF U – 10 laser methane leak detector flown on DJI UAV platforms by Remote Intelligence and TerraData Unmanned. These platforms can locate the precise point source of fugitive methane emissions and display data anywhere on any device with an AI powered globally available User Interface. 

The DJI platform is suitable for natural gas wells, compressor sites, pipelines, processing facilities, or other client facilities that require aerial methane monitoring. Integrated with geolocation, aerial photography, and thermal imaging aids response teams in pinpointing the source of the release with sensitivity down to 5 ppm at 150 feet. Monitoring results are available to the end-user as spreadsheets, shapefiles, or though the Unleash live portal, where its accessible through any connected device to secured users anywhere. 

DarkPulse through its group of companies provides premier unmanned services as part of its “Air Sea & Land” UAV, UUV and UGV solutions. The Company specializes in fully integrated, geo-rectified, 3D modeled mapping for industrial applications in the energy and environmental industries. The Company also provides aerial survey, video inspection services, emergency support services, wildlife and habitat surveys, critical infrastructure, security perimeters, bridges, culverts, dams, and similar infrastructure including underwater inspection through their UUV platforms. Integrating the latest tech solutions including artificial intelligence, DarkPulse is globally capable with operations in the U.K., Azerbaijan, Turkey, United States, Libya, Saudi Arabia and India. 

For More on DPLS Subscribe Right Now!

DPLS is making a powerful move up the charts in recent days off its base at a dime on heavy volume easily topping $5 million in dollar volume on Monday alone.  The stock is getting noticed by some pretty heavy hitter penny stock players and is currently among the most talked about and searched for stocks in small caps. Currently under heavy accumulation DPLS is looking to breakout into a whole new dimension. With recent highs set at $0.202 the stock will really take off once it breaks through this intraday high. Darkpulse is a leader in distributed fibre sensor solutions. The Companies system outperforms all other distributed fiber sensors in the market today. DarkPulse’s growing list of world-class capabilities and the Company’s positioning as the leader in infrastructure sensing and monitoring in all domains, air, land, and sea which represents an enormous market worth billions puts the Company in line for serious government contracts according to many investors who are buying in here. Darkpuse has been making big moves with the acquisiton of Optilan which recently secured leases for two new facilities located in Warwickshire in the U.K. The new facilities reinforce the Company’s innovative culture and commitment to providing industry-leading technology. The Company and Optilan have leased a new manufacturing and storage facility and a separate U.K.-based office headquarters (HQ). These new facilities represent a number of key investments the Company and Optilan are currently making to support future growth aspirations including the recently rolled out Enterprise Resource Planning system (ERP). Warwickshire is recognised as a regional hub for world class research, manufacturing, and engineering services, which reflects the positioning of the Company and Optilan. Darkpulse also just launched its Precise Point Emissions Services utilizing “around the block or around the world” capabilities. The Company’s methane detection platform comprises world class laser systems including the AILF U – 10 laser methane leak detector flown on DJI UAV platforms by Remote Intelligence and TerraData Unmanned. These platforms can locate the precise point source of fugitive methane emissions and display data anywhere on any device with an AI powered globally available User Interface. We will be updating on DPLS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with DPLS.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in DPLS either long or short and we have not been compensated for this article.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

5 days ago

on

September 19, 2023

By

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

2 weeks ago

on

September 13, 2023

By

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

2 weeks ago

on

September 12, 2023

By

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.